These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 31861871)

  • 1. Vitreous Antioxidants, Degeneration, and Vitreo-Retinopathy: Exploring the Links.
    Ankamah E; Sebag J; Ng E; Nolan JM
    Antioxidants (Basel); 2019 Dec; 9(1):. PubMed ID: 31861871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitreous and Vision Degrading Myodesopsia.
    Sebag J
    Prog Retin Eye Res; 2020 Nov; 79():100847. PubMed ID: 32151758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asteroid hyalosis-a comprehensive review.
    Khoshnevis M; Rosen S; Sebag J
    Surv Ophthalmol; 2019; 64(4):452-462. PubMed ID: 30707924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive association of pigment epithelium-derived factor with total antioxidant capacity in the vitreous fluid of patients with proliferative diabetic retinopathy.
    Yokoi M; Yamagishi S; Saito A; Yoshida Y; Matsui T; Saito W; Hirose S; Ohgami K; Kase M; Ohno S
    Br J Ophthalmol; 2007 Jul; 91(7):885-7. PubMed ID: 17301120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Limited Vitrectomy for Vision-Degrading Myodesopsia.
    Rostami B; Nguyen-Cuu J; Brown G; Brown M; Sadun AA; Sebag J
    Am J Ophthalmol; 2019 Aug; 204():1-6. PubMed ID: 30849342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy.
    Yokoi M; Yamagishi SI; Takeuchi M; Ohgami K; Okamoto T; Saito W; Muramatsu M; Imaizumi T; Ohno S
    Br J Ophthalmol; 2005 Jun; 89(6):673-5. PubMed ID: 15923499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vitreous floaters].
    Schmitz-Valckenberg S; Brasse K; Hoerauf H
    Ophthalmologe; 2020 May; 117(5):485-496. PubMed ID: 32291480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rheological Properties and Age-Related Changes of the Human Vitreous Humor.
    Tram NK; Swindle-Reilly KE
    Front Bioeng Biotechnol; 2018; 6():199. PubMed ID: 30619846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-acetylcarnosine lubricant eyedrops possess all-in-one universal antioxidant protective effects of L-carnosine in aqueous and lipid membrane environments, aldehyde scavenging, and transglycation activities inherent to cataracts: a clinical study of the new vision-saving drug N-acetylcarnosine eyedrop therapy in a database population of over 50,500 patients.
    Babizhayev MA; Micans P; Guiotto A; Kasus-Jacobi A
    Am J Ther; 2009; 16(6):517-33. PubMed ID: 19487926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of selected oxidative stress markers in the vitreous and serum of diabetic retinopathy patients.
    Brzović-Šarić V; Landeka I; Šarić B; Barberić M; Andrijašević L; Cerovski B; Oršolić N; Đikić D
    Mol Vis; 2015; 21():649-64. PubMed ID: 26120270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolomics Analysis of Human Vitreous in Diabetic Retinopathy and Rhegmatogenous Retinal Detachment.
    Haines NR; Manoharan N; Olson JL; D'Alessandro A; Reisz JA
    J Proteome Res; 2018 Jul; 17(7):2421-2427. PubMed ID: 29877085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anomalous posterior vitreous detachment: a unifying concept in vitreo-retinal disease.
    Sebag J
    Graefes Arch Clin Exp Ophthalmol; 2004 Aug; 242(8):690-8. PubMed ID: 15309558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Safety and Efficacy of Limited Vitrectomy for Vision Degrading Vitreopathy Resulting from Vitreous Floaters.
    Sebag J; Yee KMP; Nguyen JH; Nguyen-Cuu J
    Ophthalmol Retina; 2018 Sep; 2(9):881-887. PubMed ID: 31047219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proliferative vitreo-retinal disorders: experimental models in vivo and in vitro.
    Martini B
    Acta Ophthalmol Suppl (1985); 1992; (201):1-63. PubMed ID: 1322004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interfaces.
    Sebag J; Hageman GS
    Eur J Ophthalmol; 2000; 10(1):1-3. PubMed ID: 10744197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel vitreous modulators for pharmacologic vitreolysis in the treatment of diabetic retinopathy.
    Costa Ede P; Rodrigues EB; Farah ME; Sebag J; Meyer CH
    Curr Pharm Biotechnol; 2011 Mar; 12(3):410-22. PubMed ID: 20939794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of enzymatic degradation on dynamic mechanical properties of the vitreous and intravitreal nanoparticle mobility.
    Huang D; Chen YS; Xu Q; Hanes J; Rupenthal ID
    Eur J Pharm Sci; 2018 Jun; 118():124-133. PubMed ID: 29574081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and quantitation of carotenoids and their metabolites in the tissues of the human eye.
    Bernstein PS; Khachik F; Carvalho LS; Muir GJ; Zhao DY; Katz NB
    Exp Eye Res; 2001 Mar; 72(3):215-23. PubMed ID: 11180970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photoablation of Human Vitreous Opacities by Light-Induced Vapor Nanobubbles.
    Sauvage F; Fraire JC; Remaut K; Sebag J; Peynshaert K; Harrington M; Van de Velde FJ; Xiong R; Tassignon MJ; Brans T; Braeckmans K; De Smedt SC
    ACS Nano; 2019 Jul; 13(7):8401-8416. PubMed ID: 31287662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases.
    Babizhayev MA; Kasus-Jacobi A
    Curr Clin Pharmacol; 2009 Jan; 4(1):4-37. PubMed ID: 19149498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.